Tumor measurements predict survival in advanced non-small cell lung cancer

August 19, 2013

For the two-thirds of lung cancer patients with locally advanced or metastatic disease, tumor size is not used currently to predict overall survival times. A new study, however, led by UT Southwestern Medical Center researchers has shown that even in advanced stages total tumor size can have a major impact on survival.

Using data from a National Cancer Institute-sponsored Phase 3 trial involving 850 patients with advanced lung cancer, Dr. David Gerber, assistant professor of internal medicine at UT Southwestern, and colleagues from other reviewed the recorded total tumor dimensions – which may include not only the primary tumor, but also those in lymph nodes and other sites of . Dr. Gerber's team found that total tumor measurements greater than 3 inches predicted shorter survival times.

"The traditional view is that once a cancer has spread to the lymph nodes or to other organs, tumor dimensions are unlikely to affect ," explained Dr. Gerber, a member of the Harold C. Simmons Comprehensive Cancer Center and lead author of the study. "However, the survival differences we found are not only statistically significant, but also clinically meaningful."

In the study, published online in the British Journal of Cancer, the average total tumor dimension was 7.5 centimeters, or roughly 3 inches. Patients with total tumor dimensions above this size lived an average of 9.5 months. Patients with total dimensions below 7.5 centimeters lived an average of 12.6 months, representing a 30 percent increase in survival.

When total tumor dimension was further divided into quartiles, the survival differences were even greater, ranging from 8.5 months to 13.3 months. These differences persisted even when multiple , such as age, gender, and type of treatment, were included in the analysis.

Dr. Gerber explained that, if confirmed in other populations, these findings could affect future clinical trials and patient care.

"Ultimately, clinical researchers might consider this information as they review outcome data, making sure survival differences are attributed to treatment effects and not to baseline differences in total tumor dimensions," he said. "Practicing physicians may also use the information to estimate prognosis."

Precise measurements of lung cancer tumors can be used in tailoring therapy and helping doctors steer patients to the best clinical trials, he added.

While the study did not seek to explain the biological reasons why this size association may hold true, a number of preclinical observations link with therapeutic resistance. It is generally thought that as tumors grow, the proportion of cells resistant to chemotherapy increases. Larger cancers may also have relatively poor blood supply and more pronounced gradients in interstitial pressure, hypoxia, and acidity, which may influence tumor cell sensitivity to chemotherapeutics and radiation treatments.

Explore further: Nonsentinel lymph nodes key factor in melanoma prognosis

Related Stories

Nonsentinel lymph nodes key factor in melanoma prognosis

August 2, 2013
(HealthDay)—Nonsentinel lymph node (NSLN) positivity is a significant prognostic factor in patients with stage III melanoma, associated with shorter overall and disease-specific survival, according to research published ...

Oxygen—key to most life—decelerates many cancer tumors when combined with radiation therapy

July 23, 2013
July 23, 2013 – A multidisciplinary team at UT Southwestern Medical Center has found that measuring the oxygenation of tumors can be a valuable tool in guiding radiation therapy, opening the door for personalized therapies ...

New therapy strategy could help treat cancer that has spread from breast to brain

August 6, 2013
(Medical Xpress)—Researchers at UCLA's Jonsson Comprehensive Cancer Center have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that ...

Pretesting cervical tumors could inform treatment

May 31, 2013
(Medical Xpress)—Doctors at Washington University School of Medicine in St. Louis have shown that testing cervical tumors before treatment for vulnerability to chemotherapy predicts whether patients will do well or poorly ...

Patients with BRCA1 mutations, but not BRCA2 mutations, had poorer prognosis compared with noncarriers

April 9, 2013
Patients with breast cancer who had a BRCA1 mutation had significantly worse overall and recurrence-free survival rates compared with patients without BRCA mutations, but no evidence for a difference in survival was found ...

CT and serum LDH shows promise as survival predictor for some metastatic melanoma patients

April 17, 2013
Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy.

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.